Qiagen

Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).

Qiagen NV

Qiagen N.V.

Stuttgart,,Germany,-,01-19-2021:,Logo,Of,Dutch,Sample,And,Assay

Earnings

Equities

Mid Cap

News

Guidance

Movers

GNOM

QGEN

Qiagen (QGEN) shares up premarket after disclosing strong preliminary Q1 2025 results and raising full-year EPS outlook. Stock price up 3.06%.

Qiagen Shares Rise Premarket As Preliminary Q1 Results, Hikes FY25 EPS Guidance

workday shutter2

Downgrades

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

CRVO

SUPN

TCMD

TECH

WDAY

This Workday Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

Wall-Street-ai7-1

Analyst Color

Large Cap

Tech

ETFs

AMGN

AVGO

AZEK

DELL

Janus Henderson Group plc Ordinary Shares

KVYO

MNDY

NVDA

SNOW

TOST

UPST

Goldman Sachs identifies 18 stocks for potential earnings upside and advises options-based strategies in a volatile market. 10% upside for S&amp;P 500.

18 Stocks To Buy, 7 To Sell This Earnings Season: Goldman Sachs Calls It &#39;The Year Of The Stock Picker&#39;

Press Releases

QIAGEN N.V.: QIAGEN Announces Strong Preliminary Q1 2025 Results and Updates Full-Year 2025 Adjusted Earnings per Share Outlook

QIAGEN Delivers Strong Preliminary Q1 2025 Results Exceeding Outlook and Raises Full-Year 2025 Adjusted EPS Outlook

QIAGEN N.V. to Release Results for Q1 2025 and Hold Webcast

QIAGEN Advancing Plans to Launch Three New Sample Preparation Instruments by 2026 to Improve Lab Automation

QIAGEN Advances Cancer Genomic Profiling With New Products and Partnership Updates at AACR Annual Meeting 2025

QIAGEN Expands Its Digital PCR Portfolio With New Lentivirus Solutions to Strengthen Cell and Gene Therapy Quality Control

QIAGEN to Propose Initiation of Annual Cash Dividend for Shareholder Approval at Annual General Meeting

QIAGEN delivers solid Q1 2025 results exceeding outlook; will seek shareholder approval to initiate a dividend and new $500 mn repurchase

QIAGEN announces plans for transition in leadership of Supervisory Board

QIAGEN enhances leading clinical genomics portfolio with acquisition of Genoox AI-powered software

Baird

Morgan Stanley

Jefferies

Wolfe Research

Comments

Qiagen

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell